Immunotherapy of Myelodysplastic Syndrome: You Can Run, but You Can't Hide.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29284705.
- Also identified by DOI 10.1158/1078-0432.CCR-17-2960.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The hypomethylating agent decitabine induces expression of the cancer/testis antigen NY-ESO-1 in the myeloid cells of patients with myelodysplastic syndrome (MDS). Patients with MDS treated with decitabine and an NY-ESO-1 vaccine developed NY-ESO-1-specific T-cell responses directed against their abnormal myeloid cells, raising hopes for combinatorial immunotherapy of this disease. <i>Clin Cancer Res; 24(5); 991-3. ©2017 AACR</i><i>See related article by Griffiths et al., p. 1019</i>.
Medical subject headings
- Myelodysplastic Syndromes
- T-Lymphocytes